XML 43 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt - Long-Term Debt from Royalty-Bearing Instrument-December 2012 Financing - Additional Information (Detail) - USD ($)
 3 Months Ended
Dec. 06, 2012
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Debt Disclosure [Line Items]        
(Loss) gain on change in fair value of derivative liabilities     $ (1,250,000)  
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount   $ 94,118,000   $ 93,592,000
BioPharma Debt        
Debt Disclosure [Line Items]        
Amount received at the closing of the agreement $ 100,000,000      
Maximum repayment of future revenue and receivables 150,000,000 121,700,000    
Repayment under agreement   3,800,000    
Fair value of embedded derivative liability $ 14,600,000      
(Loss) gain on change in fair value of derivative liabilities   0 (400,000)  
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount   94,100,000   $ 93,600,000
BioPharma Debt | Cash        
Debt Disclosure [Line Items]        
Interest expense, contractual coupon interest   1,600,000 1,700,000  
BioPharma Debt | Non Cash        
Debt Disclosure [Line Items]        
Convertible notes, interest expense   500,000 $ 500,000  
BioPharma Debt | May 2017        
Debt Disclosure [Line Items]        
Future minimum repayment under agreement   $ 3,400,000